Ela Pharma ⚠ Under review

Under review — some data on this profile may be inaccurate and is being re-verified.

Developer of antinectrotic therapies.

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2015
Last updated 2026-07-26
Total raised
$77K
Last: Undisclosed Round 2020-12
Stage
Seed
Founded
2015
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The company's drug development process is based on a new platform for anti-necrosis technology, which directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of the necrosis pathway. Necrosis is a major mode of cell death associated with various diseases that currently lack drug-based cures, including myocardial infarction, ischemic diseases, brain stroke, traumatic brain injury, neurodegenerative diseases, liver failure, chronic hepatitis, pancreatitis, and acute macular degeneration. Ela Pharma's technology also has potential applications in organ preservation, aiming to extend the viability of organs for transplantation.

Funding history · 2 rounds · $77K total

2020-11
Undisclosed Round Undisclosed
★ Smart Funding
2019-11
Grant $77K

Q&A

What is Ela Pharma's primary focus?
Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis, utilizing a new platform for anti-necrosis technology.
Where is Ela Pharma headquartered?
Ela Pharma is headquartered in Tel Aviv-Yafo, Israel.
When was Ela Pharma founded?
Ela Pharma was founded in June 2015.
How many employees does Ela Pharma have?
Ela Pharma has 1-10 employees.
Who are the co-founders of Ela Pharma?
The co-founders of Ela Pharma are Roi Paul Nathan, who also serves as CEO, and Ilana Nathan.
What is Ela Pharma's current funding stage?
Ela Pharma is currently in the Seed funding stage.
Has Ela Pharma received any grant funding?
Yes, Ela Pharma received a Grant round in December 2019 from EU Horizon 2020, totaling $77,000.
What is Ela Pharma's technology based on?
Ela Pharma's technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme critical in regulating necrosis pathways, using small molecules as anti-necrosis agents.
Does Ela Pharma hold any patents?
Yes, Ela Pharma holds 1 patent.

Team · 2

Roi Paul Nathan
Founder · Co-founder & CEO
Ilana Nathan
Founder · Co-founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsdrug-developmentcell-therapyamyotrophic-lateral-sclerosis-alsstrokeheart-diseasesbiotechnologyischemiadegenerative-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteelapharma.com/
LinkedInlinkedin.com/company/18221536

Identifiers & details

Founded2015-6
Employees (exact)2

Radar intelligence

Patents

EPO1

Web history (Wayback)

Domainelapharma.com

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)515279156
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2015-06-28
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2023
Active charges / liens0
Registry events1 — violation (1)
Registered addressדורי 4 הרצליה

Recent registry events

DateEvent
2026-06-25עדכון הפרה